Logo image of BIIB

BIOGEN INC (BIIB) Stock Fundamental Analysis

USA - NASDAQ:BIIB - US09062X1037 - Common Stock

150.08 USD
+2.36 (+1.6%)
Last: 10/23/2025, 8:00:01 PM
150.07 USD
-0.01 (-0.01%)
After Hours: 10/23/2025, 8:00:01 PM
Fundamental Rating

5

Overall BIIB gets a fundamental rating of 5 out of 10. We evaluated BIIB against 534 industry peers in the Biotechnology industry. While BIIB has a great profitability rating, there are some minor concerns on its financial health. BIIB is cheap, but on the other hand it scores bad on growth. These ratings could make BIIB a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

BIIB had positive earnings in the past year.
In the past year BIIB had a positive cash flow from operations.
BIIB had positive earnings in each of the past 5 years.
In the past 5 years BIIB always reported a positive cash flow from operatings.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

Looking at the Return On Assets, with a value of 5.40%, BIIB belongs to the top of the industry, outperforming 91.76% of the companies in the same industry.
BIIB's Return On Equity of 8.68% is amongst the best of the industry. BIIB outperforms 92.88% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.52%, BIIB belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
BIIB had an Average Return On Invested Capital over the past 3 years of 10.57%. This is below the industry average of 15.49%.
Industry RankSector Rank
ROA 5.4%
ROE 8.68%
ROIC 9.52%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

BIIB has a Profit Margin of 15.31%. This is amongst the best in the industry. BIIB outperforms 93.63% of its industry peers.
In the last couple of years the Profit Margin of BIIB has declined.
With an excellent Operating Margin value of 27.35%, BIIB belongs to the best of the industry, outperforming 96.25% of the companies in the same industry.
BIIB's Operating Margin has declined in the last couple of years.
BIIB has a Gross Margin of 75.43%. This is amongst the best in the industry. BIIB outperforms 83.52% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.35%
PM (TTM) 15.31%
GM 75.43%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
BIIB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BIIB has an improved debt to assets ratio.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

BIIB has an Altman-Z score of 3.08. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BIIB (3.08) is better than 68.91% of its industry peers.
The Debt to FCF ratio of BIIB is 3.40, which is a good value as it means it would take BIIB, 3.40 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BIIB (3.40) is better than 93.63% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that BIIB is not too dependend on debt financing.
BIIB has a Debt to Equity ratio of 0.36. This is in the lower half of the industry: BIIB underperforms 70.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.4
Altman-Z 3.08
ROIC/WACC1.06
WACC8.99%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

A Current Ratio of 2.50 indicates that BIIB has no problem at all paying its short term obligations.
BIIB has a Current ratio of 2.50. This is in the lower half of the industry: BIIB underperforms 68.73% of its industry peers.
BIIB has a Quick Ratio of 1.79. This is a normal value and indicates that BIIB is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.79, BIIB is not doing good in the industry: 76.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 1.79
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

2

3. Growth

3.1 Past

The earnings per share for BIIB have decreased by -3.61% in the last year.
Measured over the past years, BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 3.36%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%

3.2 Future

Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 1.15% on average per year.
Based on estimates for the next years, BIIB will show a decrease in Revenue. The Revenue will decrease by -0.44% on average per year.
EPS Next Y-1.72%
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
EPS Next 5Y1.15%
Revenue Next Year0.4%
Revenue Next 2Y-1.8%
Revenue Next 3Y-1.14%
Revenue Next 5Y-0.44%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 9.37 indicates a reasonable valuation of BIIB.
Based on the Price/Earnings ratio, BIIB is valued cheaply inside the industry as 97.94% of the companies are valued more expensively.
BIIB is valuated cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.31, which indicates a very decent valuation of BIIB.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaper than 97.75% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.33. BIIB is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.37
Fwd PE 9.31
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaper than 97.57% of the companies in the same industry.
97.75% of the companies in the same industry are more expensive than BIIB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.91
EV/EBITDA 7.24
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.05%
EPS Next 3Y0.57%

More info and screens

0

5. Dividend

5.1 Amount

BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOGEN INC

NASDAQ:BIIB (10/23/2025, 8:00:01 PM)

After market: 150.07 -0.01 (-0.01%)

150.08

+2.36 (+1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners92.49%
Inst Owner Change0.22%
Ins Owners0.14%
Ins Owner Change3.4%
Market Cap22.00B
Revenue(TTM)10.00B
Net Income(TTM)1.53B
Analysts73.81
Price Target173.2 (15.41%)
Short Float %3.5%
Short Ratio3.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)0.43%
PT rev (3m)-0.43%
EPS NQ rev (1m)0.65%
EPS NQ rev (3m)-3.14%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)6.03%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)2.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.42%
Valuation
Industry RankSector Rank
PE 9.37
Fwd PE 9.31
P/S 2.2
P/FCF 11.91
P/OCF 10.4
P/B 1.25
P/tB 13.15
EV/EBITDA 7.24
EPS(TTM)16.01
EY10.67%
EPS(NY)16.13
Fwd EY10.75%
FCF(TTM)12.6
FCFY8.39%
OCF(TTM)14.44
OCFY9.62%
SpS68.19
BVpS120.28
TBVpS11.41
PEG (NY)N/A
PEG (5Y)N/A
Graham Number208.15
Profitability
Industry RankSector Rank
ROA 5.4%
ROE 8.68%
ROCE 10.87%
ROIC 9.52%
ROICexc 10.7%
ROICexgc 37.26%
OM 27.35%
PM (TTM) 15.31%
GM 75.43%
FCFM 18.47%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.4
Debt/EBITDA 1.81
Cap/Depr 36.28%
Cap/Sales 2.7%
Interest Coverage 250
Cash Conversion 60.86%
Profit Quality 120.66%
Current Ratio 2.5
Quick Ratio 1.79
Altman-Z 3.08
F-Score6
WACC8.99%
ROIC/WACC1.06
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-1.72%
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
EPS Next 5Y1.15%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.4%
Revenue Next 2Y-1.8%
Revenue Next 3Y-1.14%
Revenue Next 5Y-0.44%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y5.8%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%